Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Pfizer
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Mayo Clinic
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Mayo Clinic
Novartis
Tizona Therapeutics, Inc
Essen Biotech
Werewolf Therapeutics, Inc.
Royal Marsden NHS Foundation Trust
Sairopa B.V.
NovoCure Ltd.
VM Oncology, LLC
Transgene
NovoCure Ltd.
Hummingbird Bioscience
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Qilu Pharmaceutical Co., Ltd.
Immuneering Corporation
Incyte Corporation
Trishula Therapeutics, Inc.
NYU Langone Health
NuCana plc
Medicenna Therapeutics, Inc.
BeiGene
Bank of Cyprus Oncology Centre
M.D. Anderson Cancer Center
Phanes Therapeutics
Carisma Therapeutics Inc
NextCure, Inc.
Salubris Biotherapeutics Inc
National Cancer Institute (NCI)
Eli Lilly and Company
University of California, San Francisco
Wellmarker Bio
Augusta University
Rutgers, The State University of New Jersey
Providence Health & Services
Seagen Inc.
Incyte Corporation